Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: kim sb. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS, Lee MA, Lee J, Lee NS, Ham HS, Kim TY, Park YH, Lee KE, Kim KW, Seo JH, Lee SN, Hong YS, Bang YJ, Kim WK, Park HS. Im SA, et al. Among authors: kim sb, kim wk, kim ty, kim kw. Oncol Rep. 2005 Aug;14(2):481-7. Oncol Rep. 2005. PMID: 16012734 Clinical Trial.
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY. Kim JE, et al. Among authors: kim sb, kim hj, kim sy. Breast Cancer Res Treat. 2011 Jan;125(1):99-106. doi: 10.1007/s10549-010-1201-8. Epub 2010 Oct 5. Breast Cancer Res Treat. 2011. PMID: 20922564 Clinical Trial.
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
Xu B, Jiang Z, Kim SB, Yu S, Feng J, Malzyner A, Del Giglio A, Chung HC, Shen LJ, Pen DL. Xu B, et al. Among authors: kim sb. Breast Cancer. 2011 Jul;18(3):203-12. doi: 10.1007/s12282-011-0260-y. Epub 2011 Apr 5. Breast Cancer. 2011. PMID: 21465229 Clinical Trial.
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
Im SA, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW. Im SA, et al. Among authors: kim sb, kim jh. Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18. Breast Cancer Res Treat. 2012. PMID: 22094934 Clinical Trial.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Baselga J, et al. Among authors: kim sb. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149875 Free PMC article. Clinical Trial.
2,445 results